CA2505937C - Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropaties induced by anticancer agents - Google Patents

Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropaties induced by anticancer agents Download PDF

Info

Publication number
CA2505937C
CA2505937C CA2505937A CA2505937A CA2505937C CA 2505937 C CA2505937 C CA 2505937C CA 2505937 A CA2505937 A CA 2505937A CA 2505937 A CA2505937 A CA 2505937A CA 2505937 C CA2505937 C CA 2505937C
Authority
CA
Canada
Prior art keywords
acid
carnitine
anticancer agent
acetyl
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2505937A
Other languages
English (en)
French (fr)
Other versions
CA2505937A1 (en
Inventor
Claudio Cavazza
Claudio Pisano
Loredana Vesci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CA2505937A1 publication Critical patent/CA2505937A1/en
Application granted granted Critical
Publication of CA2505937C publication Critical patent/CA2505937C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2505937A 2002-11-13 2003-10-23 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropaties induced by anticancer agents Expired - Fee Related CA2505937C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/292,823 US20030199535A1 (en) 1998-07-30 2002-11-13 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
US10/292,823 2002-11-13
PCT/IT2003/000656 WO2004043454A1 (en) 2002-11-13 2003-10-23 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents

Publications (2)

Publication Number Publication Date
CA2505937A1 CA2505937A1 (en) 2004-05-27
CA2505937C true CA2505937C (en) 2011-07-26

Family

ID=32312146

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2505937A Expired - Fee Related CA2505937C (en) 2002-11-13 2003-10-23 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropaties induced by anticancer agents

Country Status (19)

Country Link
US (2) US20030199535A1 (enExample)
EP (1) EP1562577B1 (enExample)
JP (1) JP2006508958A (enExample)
KR (1) KR20050075012A (enExample)
CN (1) CN1708297A (enExample)
AR (1) AR041947A1 (enExample)
AT (1) ATE526958T1 (enExample)
AU (2) AU2003283807B2 (enExample)
BR (1) BR0316131A (enExample)
CA (1) CA2505937C (enExample)
CY (1) CY1112399T1 (enExample)
DK (1) DK1562577T3 (enExample)
ES (1) ES2374503T3 (enExample)
MX (1) MXPA05004752A (enExample)
PL (1) PL379244A1 (enExample)
PT (1) PT1562577E (enExample)
SI (1) SI1562577T1 (enExample)
TW (1) TWI362260B (enExample)
WO (1) WO2004043454A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018767A2 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ITMI20070817A1 (it) * 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
JP4208036B1 (ja) * 2007-04-26 2009-01-14 日本新薬株式会社 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物
WO2009028605A1 (ja) * 2007-08-31 2009-03-05 Kyushu University, National University Corporation 抗がん剤による末梢神経障害の予防又は軽減剤
AU2008348717B2 (en) * 2007-10-30 2013-09-19 Trophos Novel composition for treating the side effects of anticancer treatments
EA201170732A1 (ru) * 2008-12-01 2011-12-30 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Применение алканоил l-карнитина в комбинации с химиотерапевтическими средствами для лечения новообразований
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
ITPZ20130005A1 (it) * 2013-07-05 2015-01-06 Teodosio Antonio Ferrara Metabolismo energetico e omeostasi
CN110121563A (zh) 2016-11-09 2019-08-13 奇根科学有限责任公司 在边合成边测序中作为成像试剂的光保护混合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713370A (en) * 1972-11-06 1987-12-15 Felice Stephen L De Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
US4599352A (en) * 1984-03-01 1986-07-08 The United States Of America As Represented By The Department Of Health And Human Services Antineoplastic platinum (IV) complexes and compositions
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
DE69923322T2 (de) * 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung

Also Published As

Publication number Publication date
AU2003283807A1 (en) 2004-06-03
PT1562577E (pt) 2012-01-12
EP1562577B1 (en) 2011-10-05
ES2374503T3 (es) 2012-02-17
CY1112399T1 (el) 2015-12-09
BR0316131A (pt) 2005-09-27
US20060183798A1 (en) 2006-08-17
US20030199535A1 (en) 2003-10-23
TW200410683A (en) 2004-07-01
JP2006508958A (ja) 2006-03-16
SI1562577T1 (sl) 2012-01-31
PL379244A1 (pl) 2006-08-07
CN1708297A (zh) 2005-12-14
AR041947A1 (es) 2005-06-01
AU2003283807B2 (en) 2009-12-03
TWI362260B (en) 2012-04-21
ATE526958T1 (de) 2011-10-15
KR20050075012A (ko) 2005-07-19
WO2004043454A1 (en) 2004-05-27
AU2009201384A1 (en) 2009-05-07
CA2505937A1 (en) 2004-05-27
MXPA05004752A (es) 2005-08-02
EP1562577A1 (en) 2005-08-17
DK1562577T3 (da) 2012-01-23

Similar Documents

Publication Publication Date Title
US20080194683A1 (en) Medicament for preventing and/or treating peripheral neuropathies
AU2009201384A1 (en) Acetyl-L-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents
US5977099A (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6214860B1 (en) Synergistic antitumor composition containing a naphthalensulphonic acid derivative
US20160228409A1 (en) Compositions and Methods for Pain Relief
AU2009215329B2 (en) Combination comprising paclitaxel for treating ovarian cancer
US9040082B2 (en) Compositions and methods for treatment of chronic fatigue
JP2014522817A (ja) 慢性疲労の治療用の組成物および方法
CN102215838A (zh) 烷酰基l-肉毒碱联合化学治疗药在治疗赘生物中的应用
US4609647A (en) Cytidyl diphosphocholine-drug composition and process
CA1248454A (en) Cytidyl diphosphocholine-drug composition and process
EP0001924B1 (en) Pharmaceutical composition for administering choline
PT1492539E (pt) Terapia de estatina para intensificar a manutenção cognitiva
US8927600B2 (en) Compound for use in the treatment of peripheral neuropathies
HK1084027A (en) Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents
US20030040507A1 (en) Pharmaceutical composition comprising ifosfamide and carnitine
WO2006102337A2 (en) L-arginine and zinc supplementation for repair of intestinal epithelial cell injury
HK1035677B (en) Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity
MXPA01001065A (es) Uso de l-carnitina y sus derivados alcanoilo en la preparacion de medicamentos con actividad contra el cancer
EP1890693A2 (en) Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141023